ArticleInternational journal of general medicine2025
Thyroid Status and Pulmonary Thromboembolic Extent: Is There an Association in Patients with Pulmonary Embolism?
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid dysfunction has been associated with thrombotic diseases. However, the association between thyroid status and pulmonary thromboembolic extent remains unclear in patients with pulmonary embolism (PE). Thus, this study investigated the association between thyroid status and pulmonary thromboembolic extent and elucidated the clinical significance of thyroid status assessment in patients with PE. Methods: We retrospectively analyzed data from 118 patients with PE. Pulmonary thromboembolic extent was assessed with computerized tomography obstruction index. Results: Serum free triiodothyronine (FT3) levels were significantly higher in PE patients with greater pulmonary thromboembolic extent than in those with lesser pulmonary thromboembolic extent (4.33[4.04-4.98] vs 4.17[3.33-4.66] pmol/L, p=0.017), but not for serum free thyroxine (FT4) levels (15.33[13.43-16.94] vs 15.36[13.75-17.82] pmol/L, p=0.908) and serum thyroid stimulating hormone (TSH) levels (1.84[1.01-3.00] vs 1.49[0.74-2.58] uIU/mL, p=0.273). Multivariable linear regression analysis revealed that higher serum FT3 levels were independently associated with greater pulmonary thromboembolic extent in patients with PE (β=0.235, p=0.013). Conclusion: Higher serum FT3 levels were associated with greater pulmonary thromboembolic extent in patients with PE. This finding suggests that the possibility of extensive pulmonary thromboembolic extent should be noticed for PE patients with higher serum FT3 levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.